Outstanding outcomes in infants with KMT2A-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children's Oncology Group AALL0631 trial

Creator(s)

Erin M. Guest, Children's Mercy HospitalFollow
John A. Kairalla
Joanne M. Hilden
ZoAnn E. Dreyer
Andrew J. Carroll
Nyla A. Heerema
Cindy Y. Wang
Meenakshi Devidas
Lia Gore
Wanda L. Salzer
Naomi J. Winick
William L. Carroll
Elizabeth A. Raetz
Michael Borowitz
Mignon L. Loh
Stephen P. Hunger
Patrick A. Brown

Document Type

Letter to the Editor

Publication Date

5-1-2022

Identifier

DOI: 10.3324/haematol.2021.280146

Journal Title

Haematologica

Volume

107

Issue

5

First Page

1205

Last Page

1208

MeSH Keywords

Clinical Trials as Topic; Germ Cells; Humans; Infant; Myeloid-Lymphoid Leukemia Protein; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome

Keywords

Clinical Trials as Topic; Germ Cells; Myeloid-Lymphoid Leukemia Protein; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome

Comments

Grant support

• U10 CA180899/CA/NCI NIH HHS/United States

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Publisher's Link: https://haematologica.org/article/view/haematol.2021.280146

Recommended Citation

Guest EM, Kairalla JA, Hilden JM, et al. Outstanding outcomes in infants with KMT2A-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children's Oncology Group AALL0631 trial. Haematologica. 2022;107(5):1205-1208. Published 2022 May 1. doi:10.3324/haematol.2021.280146